Skip to main content
. 2025 May 21;17:111. doi: 10.1186/s13195-025-01751-5

Table 1.

Cohort characteristics

Alzheimer’s disease (N = 70) Dementia with Lewy bodies (N = 29) Mixed AD (+ CVD)
(N = 8)
Vascular cognitive dysfunction
(N = 15)
Healthy control
(N = 48)
P-value
Age (years), mean (SD) 75.3 (7.1) 76.2 (6.4) 81.8 (3.3) 78.5 (5.9) 71.1 (7.8) < 0.0011
Sex, n (%)
 Female 33 (47.1%) 4 (13.8%) 4 (50.0%) 5 (33.3%) 30 (62.5%) < 0.0012
 Male 37 (52.9%) 25 (86.2%) 4 (50.0%) 10 (66.7%) 18 (37.5%)

MMSE total score,

mean (SD)

25.5 (2.7) 26.2 (2.9) 22.6 (2.8) 26.5 (2.9) 29.1 (1.1) < 0.0013
Educational level (years), mean (SD) 11.8 (3.7) 13 (4) 13.3 (4.7) 10.5 (2.9) 15 (2.5) < 0.0013
Disease severity, n(%)
 Mild cognitive impairment 21 (30.0%) 3 (10.3%) 0 (0.0%) 8 (53.3%) - < 0.0012
 Mild dementia 46 (65.7%) 25 (86.2%) 5 (62.5%) 4 (26.7%) -
 Moderate dementia 3 (4.3%) 1 (3.4%) 3 (37.5%) 3 (20.0%) -
Objective gait impairment, n (%)
 No 63 (90.0%) 11 (37.9%) 4 (50.0%) 8 (53.3%) 45 (93.8%) < 0.0012
 Yes 7 (10.0%) 17 (58.6%) 4 (50.0%) 6 (40.0%) 3 (6.2%)
Subjective maximum walking distance (meters), mean (SD) 6137 (3205) 4598 (3473) 1775 (1639) 3314 (3303) 7523 (3144) < 0.0013
Hypnotic medication, n (%)
 Yes 1 (1.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.6972
Previous stroke, n (%)
 Yes 2 (2.9%) 1 (3.4%) 2 (25.0%) 5 (33.3%) 0 (0.0%) < 0.0012
Sedatives or analgesic medication, n (%)
 Yes 1 (1.4%) 2 (6.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.1262
Antidepressant medicine, n (%)
 Yes 6 (8.6%) 4 (13.8%) 1 (12.5%) 3 (20.0%) 3 (6.2%) 0.4292
Antipsychotic medication, n (%)
 Yes 1 (1.4%) 1 (3.4%) 0 (0.0%) 1 (6.7%) 0 (0.0%) 0.5192
Antidementia medication, n (%)
 Yes 29 (41.4%) 22 (75.9%) 6 (75.0%) 0 (0.0%) 0 (0.0%) < 0.0012

All variables had < 5 missing values. Frequency is calculated for participants without missing data

1ANOVA

2Fisher’s Exact Test

3Kruskal-Wallis rank sum test